BACKGROUND: The current study aimed to investigate whether the novel @entity1501 (FT) modified nanoparticles (NPs) co-loaded with @entity1205 (DT) and @entity6108 (CU) (named as FT-NPs) could enhance the delivery efficiency to @entity5 compared with the NPs without FT (non-targeted NPs). METHODS: FT-NPs were successfully formulated in this article. In vitro cytotoxic activity against A549 cells and in vivo antitumor activity of FT-NPs in S180 cell bearing @entity19 were conducted. Cellular uptake test was used to evaluate uptake efficiency of FT-NPs. Histological observation was used to determine the lung security. Besides, the physical chemical properties such as stability, particle size, zeta potential, drug encapsulation efficiency, transmission electron microscopy (TEM) were also conducted. RESULTS: FT-NPs exhibited stronger growth inhibition effects on A549 cells compared with non-targeted NPs, moreover, the novel FT-NPs indicated more effective antitumor efficacy in inhibiting @entity5 growth. Confocal laser scanning microscopy indicated that the uptake of FT-NPs was facilitated and effective. Histological observation meant that FT-NPs were biocompatible and appropriate for pulmonary administration. CONCLUSION: These results confirmed that FT-NPs with relatively high drug loading capacity could effectively inhibit @entity5 growth and reduce @entity137 . The novel FT-NPs could produce as an outstanding nanocarrier for the targeted treatment of @entity5 .

Enhanced antitumor efficacy of folate targeted nanoparticles co-loaded with @entity1205 and XXXX .

@entity1501 :: ('MESH:D005492', 'Chemical') :: ['folate'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers'] @entity6108 :: ('MESH:D003474', 'Chemical') :: ['curcumin'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']
@entity6108 :: (MESH:D003474,Chemical) :: ['curcumin']
